SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnold silver who wrote (26)10/9/1997 1:26:00 AM
From: James Silverman   of 127
 
Their kidney drug looks excellent and is seemingly a great advance over existing therapies. Sales estimates of $200M worldwide look realistic. With 13M shares out there and given 50% of profits, what kind of eps figures will this translate to? Their cholesterol lowering agent is very interesting and it appears obvious they are going to try to market this as a very neglible side effect drug to be used in combo with Statins which do have some side effects, thereby allowing for lower dosing, lower side effects and improved results. GELX has also announced they are looking into getting a hand on the "fat" drug market. If they could concoct something here, it could be a nice prospect, given the benign nature of their technology, ie little to no side effects.
Personally, I see the stock much higher over the next 2-3 years, potentially several fold as they ramp up to solid profitability with an advancing pipeline.
If you find a stock you expect to markedly outperform this one, do let us know!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News